![]() |
市場調查報告書
商品編碼
1734976
醫療事務的評價(美國)- 腎細胞癌症Medical Affairs Reputations (US) - Renal Cell Carcinoma |
根據最近對100位美國腫瘤學家的調查,一些最大品牌的腎細胞癌醫療事務團隊在幾個關鍵領域的表現仍有待提升。我們揭示了醫生們認為自己做得好的方面、他們希望改進的方面以及不滿意的原因。在本報告中,我們揭示了醫療事務如何滿足腎細胞癌治療醫師的高期望。我們比較了各公司領先的腎細胞癌療法的醫療事務團隊的當前表現。
本報告基於定量調查,調查對像是透過 LiMATM 選出的醫生。 LiMATM 是全球最大的醫生名錄,擁有超過 300 萬名已識別的醫生。每位醫生均經過嚴格的篩選標準精心挑選,以確保收集到的見解具有相關性、可靠性,並反映頂尖醫療專業人士的真實感受和經驗。研究結果以易於理解的圖表形式呈現,方便您快速消化和分析數據。憑藉 LiMATM 的廣泛覆蓋範圍和精準度,FirstView Reports 提供無與倫比的數據驅動洞察,指導您的策略規劃,並在快速發展的醫療保健領域保持領先地位。
FirstWord Reports 是值得信賴的行業領導者,專注於製藥業,為生物製藥專業人士和決策者提供詳細且可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察,幫助您掌握新興趨勢,有效應對複雜課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖的獨立、公正的見解,我們的報告能夠提供您所需的準確性和可靠性。獨家獨家訪談和數據,以及持續的市場監測,讓您全面洞察市場動態。我們的報告涵蓋 40 多個活躍疾病領域,匯集醫生情報(包括 KOL 洞察和定量醫生調查),以及行業專家對醫療事務、數位醫療、銷售與行銷、市場准入及其他領域問題的看法,助您做出更明智的數據驅動決策,在快速變化的行業中保持競爭力。
According to this latest survey of 100 US oncologists, the performance of renal cell carcinoma medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating renal cell carcinoma. It compares the current performance of medical affairs teams for several leading treatments for renal cell carcinoma from various companies.
FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.